Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | CCKAR | P32238 | 10/20 | 0.44 |
| ▸ | CCKBR | P32239 | 10/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20567478 | 1.00 | GLP1R (0.54) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL20567479 | 1.00 | GLP1R (0.54) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052714 | 1.00 | GLP1R (0.54) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL19126675 | 0.91 | GLP1R (0.51) | GLP1RCCKARCCKBR | |
| SCHEMBL20672966 | 0.90 | GLP1R (0.53) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL19152955 | 0.90 | GLP1R (0.53) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL20672965 | 0.90 | GLP1R (0.42) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052652 | 0.89 | GLP1R (0.60) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052653 | 0.89 | GLP1R (0.56) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL10052636 | 0.89 | GLP1R (0.60) | GLP1RFOLH1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | NOVO NORDISK AS (DK) | 2023-11-16 | — | — | US | disclosed |
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | NOVO NORDISK AS (DK) | 2023-11-16 | — | — | US | disclosed |
| EP-3402811-B1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK AS (DK) | 2022-03-30 | — | — | EP | disclosed |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | CHEN JIANHE (CN) | 2020-12-31 | — | — | US | disclosed |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | CHEN JIANHE (CN) | 2020-12-31 | — | — | US | disclosed |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | NOVO NORDISK A/S (DK) | 2020-11-03 | — | — | US | disclosed |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | NOVO NORDISK A/S (DK) | 2020-11-03 | — | — | US | disclosed |
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2020-05-28 | — | — | US | disclosed |
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2020-05-28 | — | — | US | disclosed |
| EP-3655426-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | Novo Nordisk A/S (DK) | 2020-05-27 | — | — | EP | disclosed |
| US-9655974-B2 | N-terminal modified FGF21 compounds | NOVO NORDISK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-20140018290-A1 | LEPTIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2014-01-16 | — | — | US | disclosed |
| US-20140018290-A1 | LEPTIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2014-01-16 | — | — | US | disclosed |
| EP-2667899-A1 | LEPTIN DERIVATIVES | Novo Nordisk A/S (DK) | 2013-12-04 | — | — | EP | disclosed |
| US-20130190232-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | NOVO NORDISK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| EP-2595647-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | Novo Nordisk A/S (DK) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012101124-A1 | LEPTIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101124-A1 | LEPTIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012010553-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010553-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | IMMT, MICA, TAP1 | GLP1R 710/4885FOLH1 1511/4885CCKAR 1112/4885 |
| US-20200165313-A1 | EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF | EGFR, VEGFA, ERBB2 | GLP1R 30/4885FOLH1 1480/4885CCKAR 171/4885 |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | EGFR, LDLR, FFAR2 | GLP1R 39/4885FOLH1 1459/4885CCKAR 249/4885 |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | GLP1R 39/4885FOLH1 1459/4885CCKAR 249/4885 |
| US-20140018290-A1 | LEPTIN DERIVATIVES | FABP4, ADIPOR1, ADIPOR2 | GLP1R 10/4885FOLH1 595/4885CCKAR 231/4885 |
| US-20130190232-A1 | N-TERMINAL MODIFIED FGF21 COMPOUNDS | FABP1, LIPC, GLP1R | GLP1R 3/4885FOLH1 1645/4885CCKAR 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.